IQVIA Holdings Inc. (IQV)
Quantitative Summary
DeterministicAt 22.6x earnings — a 65% discount to the sector average of 65.2x — IQV is in the lower valuation range. Financial health is average: Piotroski 4/9, Altman Z 1.8. DCF fair value of $110 implies 36% downside based on model assumptions.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe capital allocation efficiency of IQVIA Holdings Inc. presents a structural challenge, evidenced by an ROIC-WACC spread of -1.9%, indicating that current returns fail to cover the cost of capital despite a robust DuPont-decomposed ROE of 20.5%. This high return on equity is driven primarily by significant financial leverage (Equity Multiplier at 4.52x) rather than operational margin expansion or asset efficiency, as Net Margins sit at just 8.3% and Asset Turnover remains low at 0.54x. Credit risk metrics further complicate the fundamental picture; an Altman Z-Score of 1.8 places the firm in a "grey zone" suggestive of potential distress, while a Piotroski F-Score of 4/9 reflects weak financial strength relative to peers. Conversely, the Beneish M-Score of -2.59 signals low earnings manipulation risk, suggesting that reported figures likely reflect genuine operational performance rather than accounting distortions.
Valuation metrics indicate substantial downside pressure when viewed through a discounted cash flow lens, with a fair value estimate of $107 implying 37% downside from current levels. The market is pricing in aggressive long-term free cash flow growth assumptions of 12.1% annually over the next decade, yet this optimism contrasts sharply with the company's actual revenue trajectory of only 5.9% year-over-year. Relative to its healthcare sector peers averaging a P/E multiple of 36.8x, IQVIA trades at a discount of approximately 40%, currently valued at 22.1x. However, this valuation premium relative to historical norms and the significant gap between implied growth expectations and realized sales expansion suggest that current pricing may already incorporate optimistic recovery scenarios not yet supported by cash flow generation.
Risk-adjusted performance data reveals persistent underperformance across key factor models, with a Fama-French Alpha of -23.61% annually highlighting consistent failure to generate excess returns relative to risk. The stock exhibits distinct tilts away from value and profitability factors, registering negative exposure in both the HML (-0.422) and RMW (-0.397) dimensions, which aligns with its growth-oriented but low-margin business model. Insider activity over the past 90 days remains neutral at $0 flow, offering no clear directional signal from management regarding future capital deployment or strategic shifts. Collectively, these factors paint a picture of a company trading below sector multiples that struggles to generate returns exceeding its cost of capital while relying heavily on leverage and facing skepticism among factor-based investors.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
Interactive5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.
The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of 6% YoY revenue.
Sensitivity Matrix
| TG ↓ / WACC → | 8.3% | 10.3% | 12.3% |
|---|---|---|---|
| 2% | $142 | $95 | $66 |
| 3% | $171 | $110 | $75 |
| 4% | $214 | $129 | $86 |
Center = base case. Green = >10% upside, Red = >10% downside vs $180.64.
Pre-computed DCF: WACC=10.3%, terminal growth 3%. Fair value $110 (-36.3%). Not investment advice.
Valuation Context
Currently trading 32% below its 5-year average P/E of 31.3x.
Price Chart with Moving Averages
Technical Setup
AI GeneratedIQVIA Holdings Inc. is currently trading at $167.90 within the healthcare sector, presenting a specific technical snapshot for analysis. The immediate assessment relies on the relationship between price action and moving averages to gauge trend direction, though precise average values are not provided in the current data set. Without explicit figures for short-term or long-term moving averages, it remains impossible to definitively state whether the stock is trading above or below these key benchmarks at this exact moment. Consequently, any determination regarding a bullish or bearish trend based on price position relative to moving averages requires supplementary data points that are currently absent from the provided context. Regarding short-term momentum, the Relative Strength Index (RSI) is mentioned as a critical indicator but lacks specific numerical values in the available information. In the absence of an RSI reading, one cannot ascertain if the asset is experiencing overbought conditions or oversold states, nor can the strength of recent price movements be quantified relative to its historical range. The current technical picture therefore highlights a gap in data necessary for a complete momentum analysis. Investors must await further disclosure regarding specific moving average levels and RSI percentages before forming a conclusive view on whether short-term forces are driving prices upward or downward with significant conviction.
Quant Health Deep Dive
Profitability & Value Creation
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this stock's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like XLV or VOE, the fund manager is mechanically forced to buy or sell IQV shares regardless of IQVIA Holdings Inc.'s individual fundamentals. We estimate $4.0B of passive capital is structurally linked to IQV through 8 tracked ETFs. Index rebalances and ETF creation/redemption cycles can create noticeable volume spikes unrelated to company news.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in IQVIA Holdings Inc. to visualize passive redemption contagion across ETFs and collateral stocks.
If IQVIA Holdings Inc. (IQV) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies ELI LILLY + CO (LLY) as the most exposed collateral stock, sharing 1 ETFs with IQV. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 26 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
IQV Ownership Dynamics
Passive funds hold 1 in every 7 IQV shares, reducing daily market volatility.
IQVIA Holdings Inc. (IQV) exerts measurable gravity on the passive index market, currently representing 0.5% of the State Street Health Care Select Sector SPDR ETF (XLV) and 0.5% of the VOE (VOE). Across 26 tracked ETFs, approximately 25M shares (14.9% of float) are held by passive funds and rarely trade on the open market. This level of passive ownership means index rebalances can create outsized volume events.
ETFs with Highest IQV Exposure
Float lock-up computed from 26 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
IQV Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for IQVIA Holdings Inc. over the past year sits near $166.83 (13% of 252-day volume). The current price of $180.64 trades 8.3% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (13% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
IQV Capital Efficiency
How efficiently does IQVIA Holdings Inc. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
IQVIA Holdings Inc. converts 59% of its EBITDA into free cash flow, a healthy conversion rate indicating efficient capital management — the business generates substantial cash after reinvestment. However, the ROIC-WACC spread is negative (-1.8%), suggesting reinvested capital is destroying shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-13 | 547 | $175.06 | $95,757.82 |
| 2026-05-06 | 16,409 | $176.42 | $2.9M |
| 2026-04-13 | 3,326 | $167.34 | $556,572.84 |
| 2026-03-25 | 17 | $166.09 | $2,823.53 |
| 2026-03-24 | 3 | $166.96 | $500.88 |
| 2026-03-20 | 1,550 | $166.47 | $258,028.5 |
| 2026-03-18 | 1 | $168.43 | $168.43 |
| 2026-03-16 | 8,593 | $164.72 | $1.4M |
| 2026-02-25 | 125 | $164.88 | $20,610 |
| 2026-02-23 | 31,249 | $165.62 | $5.2M |
| 2026-02-20 | 811 | $169.36 | $137,350.96 |
| 2026-02-19 | 30 | $171.06 | $5,131.8 |
| 2026-02-17 | 43,474 | $166.94 | $7.3M |
| 2026-02-10 | 2,253 | $192.67 | $434,085.51 |
| 2026-02-09 | 26,430 | $187.49 | $5.0M |
| 2026-02-05 | 1,717 | $202.54 | $347,761.18 |
| 2026-02-03 | 115 | $231.23 | $26,591.45 |
| 2026-01-21 | 36,958 | $233.69 | $8.6M |
| 2026-01-14 | 11,394 | $241.57 | $2.8M |
| 2026-01-09 | 4 | $243.19 | $972.76 |
| 2025-12-23 | 3 | $224.37 | $673.11 |
| 2025-12-22 | 256 | $220.69 | $56,496.64 |
| 2025-12-19 | 89 | $222.52 | $19,804.28 |
| 2025-12-11 | 8,543 | $222.92 | $1.9M |
| 2025-12-04 | 5,943 | $227.24 | $1.4M |
| 2025-12-01 | 13 | $230.01 | $2,990.13 |
| 2025-11-24 | 184 | $224.90 | $41,381.6 |
| 2025-11-18 | 59 | $216.12 | $12,751.08 |
| 2025-11-06 | 2 | $210.12 | $420.24 |
| 2025-10-23 | 900 | $217.86 | $196,074 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
Price Correlations
Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.
| Peer | 252-Day (1Y) | 126-Day (6M) | Direction |
|---|---|---|---|
| WTGXX | NaN | NaN | |
| TMO | 0.723 | 0.638 | High co-movement |
| A | 0.666 | 0.534 | Moderate |
| DHR | 0.649 | 0.554 | Moderate |
| MTD | 0.620 | 0.414 | Moderate |
| TXG | 0.552 | 0.440 | Moderate |
| PFE | 0.530 | 0.390 | Moderate |
| ILMN | 0.501 | 0.297 | Moderate |
| WAT | 0.494 | 0.312 | Moderate |
| GEHC | 0.490 | 0.378 | Moderate |
Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.
Compare IQV to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.